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Abstract
Background: A disintegrin and metalloproteinase (ADAMs) have been associated with multiple malignancies.
ADAMs are involved in cell fusion, cell migration, membrane protein shedding and proteolysis. ADAM8 has been
found to be overexpressed in squamous cell carcinomas of the lung. A new study showed that ADAM8 is
significantly overexpressed in metastasis of squamous cell carcinomas of the head and neck (HNSCC).
Methods: We determined ADAM8 levels in the serum of 79 HNSCC patients at the time of diagnosis, in 35
patients 3 months after treatment and in 10 patients 1 year after therapy and compared the results to the sera of
31 healthy volunteers. We also constructed tissue microarrays to detect ADAM8 immunohistochemically in 100
patients. The results were correlated with the survival data of the patients to determine the diagnostic and
prognostic value.
Results: The data demonstrated that patients with high ADAM8 expression in the tumor have worse survival rates.
We found that high ADAM8 serum levels correlated with high ADAM8 expression in tumor samples. Soluble
ADAM8 levels did not show any prognostic or diagnostic properties.
Conclusion: In summary ADAM8 expression is a prognostic factor for survival of patients with head and neck
squamous cell carcinoma.
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Background
Worldwide more than half a million patients are diag-
nosed with HNSCC [1]. The global mortality rate is 6/
100.000 [2]. The incidence of head and neck cancer in
Austria, according to the Austrian Federal Institute for
Statistics (Statistik Austria) is approximately 1000 per
year. With a ratio between 2:1 and 4:1 males are
affected more than women. Currently, the most com-
monly used prognostic and predictive factors are the
TNM staging system (AJCC, 6th Edition Cancer Staging
Atlas) and the presence of HPV/p16 [3]. Additional reli-
able predictive or prognostic tests would be very helpful
to determine the best type of treatment for our patients.
“A disintegrin and metalloproteinase"(ADAMs) are a
family of proteins, which are similar to the reprolysin
family of snake venomases. These reprolysin families
share the metalloproteinase domain with matrix metal-
loproteinases (MMPs) [4].
ADAMs are known to play a role in cell-cell and cell-
matrix interactions through the disintegrin domain [5].
ADAMs are cell surface and extracellular multidomain
proteins involved in cell-cell signaling, cell adhesion and
cell migration, cell fusion, membrane protein shedding
and proteolysis [4]. They therefore are thought to pro-
mote tumor growth [6,7]. Matrix metalloproteinases
have been identified to play a role in the infiltration of
tumors into the surrounding tissue by having the ability
of destroying extracellular matrix including the base-
ment membrane [8].
Overexpression of ADAM8 has been shown in renal
cell carcinomas, in pancreatic cancer [9], in prostate
cancer [6] and in primary brain tumors [10]. In this cur-
rent study we wanted to identify the prognostic value of
ADAM8 serum and tumor levels in HNSCC.
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mas of the lung ADAM8 was significantly overexpressed
compared to a healthy control group [11]. They also
showed that transfection of ADAM8 into tumor cells
elevated the invasiveness [2]. The aim of the study was
to determine the relevance of the protein in HNSCC.
Therefore we investigated ADAM8 serum levels and
tumor expression in tumor patients and correlated the
results to patients’ clinical data.
Methods
Patients
In our study 148 patients with squamous cell carcinoma
of the head and neck were included prospectively, all
diagnosed at the Department of Otolaryngology of the
Medical University of Vienna. The inclusion criterion
was the presence of a previously untreated, histologically
proven squamous cell carcinoma of the oropharynx,
hypopharynx, oral cavity or larynx. Exclusion criteria
were infectious diseases, immunosuppression and malig-
nancies other than squamous cell carcinoma of the
upper respiratory tract.
All patients underwent a physical examination with
special attention to the head and neck region, a panen-
doscopy, a complete blood count, a biochemical analysis
of liver and kidney function and electrolytes, an electro-
cardiogram, chest x-rays, an abdominal ultrasound, a
computed tomography scan of the head and neck and
the medical history were obtained.
The tumor samples were taken during diagnostic
panendoscopy. Blood samples were taken at the time of
diagnosis, 3 months and 12 months after the end of
therapy, respectively. In addition, serum of 31 healthy
volunteers who were selected to approximate the age
range in patient samples served as control.
Tumor samples from 100 patients were available for
immunohistochemical analysis. Tumor and blood sam-
ples were taken from 31 patients and used to compare
immunohistochemistry to Elisa results. The median
observation period was 32 months (range 25-40
months). Of the 148 patients included, 66 were primar-
ily operated, 79 received primary radiotherapy and 3
refused treatment.
The patients were primarily Caucasian and male.
T h e r ew e r e3 1f e m a l ep a t i e n t sa n d1 1 7m a l ep a t i e n t s .
Of the 79 patients whose serums were analyzed 11 were
women and 68 were men. The carcinomas which were
included were distributed as follows: 30 Hypopharynx
carcinomas, 24 carcinomas of the oral cavity, 34 carci-
nomas of the tongue, 25 carcinomas of the Larynx, 35
Oropharynx carcinomas including 18 carcinomas of the
tonsils. The patients primarily had advanced tumor
stages. 50 patients had a T1/T2 carcinoma, 98 had a
T3/T4.
Radiotherapy was performed using external beam irra-
diation with a final dose of 72 Gy in fractions of 1.8 Gy.
Chemotherapy consisted of Cisplatin 100 mg/m
2/day on
weeks 1 and 3.
All samples were obtained after informed consent and
collected using protocols approved by the Institutional
Review Board.
Tissue microarray
Before analysis, hematoxylin-eosin-stained sections from
each tumor sample were reevaluated and the suitability
of inclusion in the study was determined. Sections of 2
to 3 μm were used for the analysis. The suitability of
the tissue was evaluated using a number of inclusion
criteria such as the size (1-2 mm in depth and at least 5
mm in length and width), as well as other features, such
as appropriate fixation, absence of significant electrosur-
gical device lesions, signs of acidic decalcifying agents,
and the presence of usable tissue in each block. Each
hematoxylin-eosin-stained slide was reevaluated and
mapped to identify the specific areas for tissue acquisi-
tion to build the tissue microarrays using a manual tis-
sue arrayer (MTA-1; Beecher Instruments, Sun Prairie,
WI). Core diameter was 0.6 mm. 3 cores were used per
patient. We constructed tumor tissue microarrays from
100 paraffin embedded tumor samples.
Immunohistochemistry
Before analyzing the samples the optimal dilution ratio
and best choice of retrieval buffer was determined. To
determine the expression of ADAM8 we stained the tis-
sue microarrays with a commercially available antibody
specific for ADAM8.
Paraffin embedding was removed from the microarray
slides and after rehydration they were subjected to anti-
gen retrieval in a microwave oven (600 W) employing
Tris-EDTA buffer followed by 3 wash cycles with TBS
buffer for 5 min. Unspecific binding was avoided by
adding 5% TBS/BSA for 1 h at room temperature. Then
the primary antibody (ADAM8, 1:100, mouse IgM)
(MBL, USA) was applied and incubated overnight at 4°
in a wet chamber. A sample without primary antibody
was used as negative control. The next day the second-
ary biotinylated antibody (1:200, Multilink, Dako, DK) in
1% TBS/BSA was applied and incubated for 1 h at room
temperature. After another washing cycle alkaline phos-
phatase conjugated Streptavidin-AP/TBS/BSA (1:250,
Dako, DK) was applied for 1 h at room temperature.
Visualization was performed by fast red (Sigma, Mis-
souri, USA) and counterstained by haemalaun. Samples
were analyzed using an Olympus BH-2 microscope.
Afterwards three independent investigators (M.B., B.E.,
S.S.) analyzed the staining intensity by assigning each to
one of 3 levels. 0 is no staining, 1 is moderate staining,
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repeating the evaluation of protein expression at two
different time points and without knowledge of patients’
clinical data. Mean IS was calculated from the three
samples per patient.
ELISA
Serum ADAM8 levels were determined in 79 head and
neck cancer patients before treatment, in 35 patients
after treatment and in 10 patients 1 year after therapy
and in 31 controls by using a commercially available
enzyme test kit (R&D System Inc., USA).
The manufacturer’s instructions were strictly followed.
As a control one well was used without antibody. In
short: after coating a 96-well micro plate with a mono-
clonal antibody specific for ADAM8 and incubated over
night, the sera diluted 2:1 with the reagent diluent was
added and allowed to incubate for 2 h at room tempera-
ture. After washing off the unbound substances the
detection antibody was added, incubated for 2 h. After
another washing step Streptavidin-HRP was added and
incubated for 20 min. At the end the substrate solution
was added to the wells. The color-reaction was stopped
after 20 min by adding 50 μlo f2N H
2SO4.
The color reaction in the different wells was measured
by a microplate reader set to 450 nm with a wavelength
correction of 540 nm.
Statistical analysis
The overall significance level was set to be 0,05. The
remaining significance level was distributed to 5 hypoth-
esis [12].
To calculate the prognostic survival of the immuno-
histochemistry results the “Logrank-Test"was used and
then shown in a Kaplan-Meier curve. To compare the
ADAM8 serum levels of the 4 different groups a Krus-
kal-Willis rank sum test was used.
To test for trend of ADAM8 serum levels with rising
immunohistologic grade of tumor samples a Jonckheere-
Terpstra test was carried out. The difference of ADAM8
serum concentration between early and advanced patients
was determined by a Wilcoxon rank sum test with conti-
nuity correction. This test was also used to evaluate if
there was a difference in the serum level of ADAM8
between the healthy control group and patients with
HNSCC. To determine the prognostic value of ADAM8
serum levels a Wilcoxon rank sum test was used.
Results
Clinical data
In total 148 patients were included in the study of
which 27 were women and 121 were men. The median
age was 58 years (range 21-88 years) for the patients
and 57 years (range 39-81 years) for the control group.
At time of diagnosis blood samples were taken from
79 patients, after 3 months 35 patients were available
for a second serum sampling and after 1 year there were
10 patients for a third serum sampling. The remaining
patients could not be analyzed for the following reasons:
12 had died, 6 were lost for follow up and the remaining
were not able to come to our department in time for
blood sampling.
The statistical analysis showed that expression levels
of ADAM8 in immunohistochemistry corresponded
with survival (p-value = 0.011, JT = 4380). Examples of
the immunohistochemistry staining can be found in Fig-
ure 1. Patients with tumors overexpressing ADAM8
have significantly worse survival (see Figure 2). ADAM8
serum levels in the ELISA correlated well with immuno-
histochemistry expression levels, (p-value = 0.019). The
correlation of the results of immunohistochemistry and
ELISA is shown in Figure 3. We, however, did not find
a correlation between soluble ADAM8 levels and
patients’ survival (p-value = 0.128).
We could not demonstrate a significant difference
between ADAM8 serum levels of patients with HNSCC
at the time of diagnosis compared to the healthy
controls.
(p-value = 0.325). The comparison of soluble ADAM8
in early (T1/2, N0) and advanced (T3/4, N+) tumor
stages did also not reveal a significant difference.
There was a difference of ADAM8 serum levels at dif-
ferent stages of disease when comparing pre-therapeutic
patients, patients 3 months after therapy and patients 12
months after therapy (p-value = 0.010). The healthy
control group and patients 3 months after therapy had
higher ADAM8 serum levels than patients at the time
of diagnosis and 12 months after therapy (see Figure 4).
Figure 1 Pictures of immunohistochemical staining of ADAM8,
200 × magnification. A and B: ADAM8 negative, C and D: ADAM8
positive.
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51 patients had no staining, 45 had moderate staining
and 4 had strong staining.
Discussion
In the prospective study we analyzed the utility of
ADAM8 as a diagnostic and prognostic tool in patients
with head and neck squamous cell carcinomas.
Squamous cell carcinomas of the head and neck have
a high morbidity and mortality rate mainly because of
their high invasive and metastatic potential and high
recurrence rates. The prognosis and the quality of life of
patients with SCC of the head and neck have improved,
but not as much as in other entities. The often late
diagnosis of these cancers is one of the main problems.
A diagnostic blood test to facilitate early tumor detec-
tion would therefore be of great importance.
Metalloproteinases have been shown to play a role in
the infiltration of tumors into surrounding tissue. Since
HNSCCs have an especially high tendency for infiltra-
tion these proteinases have been a focus of investigation.
HNSCC spread to cervical lymph nodes and result in
distant metastasis, high rate of recurrence and high risk
of second malignancies [8]. Stokes and colleagues were
the first to associate ADAM8 with HNSCC [13]. They
found that ADAM8 was expressed significantly higher
in metastatic tumors as well as identifying several pro-
teinases of the ADAM-family (ADAM9, ADAM17,
ADAM28, ADAMTS1, ADAMTS8 and ADAMTS15)
-including ADAM8- which are HNSCC associated [13].
To date the clinical value of ADAM8 is still unknown.
Our study was the first to compare serum and tumor
levels of ADAM8 in the same patients with HNSCC.
We found that elevated serum levels of ADAM8 corre-
sponded with high expression of ADAM8 in tumor sam-
ples (p-value = 0.011, Jonckheere Terpstra = 4380).
The survival analysis of our study clearly demon-
strated that a high ADAM8 expression in the tissue
Figure 2 Kaplan- Meier Curve of immunohistochemistry results
divided in two groups (staining < 1 and staining ≥ 1).0
represents no staining, 1 represents moderate and 2 represents
strong staining. Mean IS was calculated from the three samples per
patient.
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Figure 3 Correlation of immunohistochemistry results and
ELISA results. X-Axis: Immunohistochemistry staining. Y-Axis: Elisa
results at time of diagnosis.
Figure 4 Boxplots of the serum levels of ADAM8 in all 4
groups. Healthy represents the ADAM8 expression in the healthy
control group N = 31, tu00 represents the ADAM8 expression in the
serum of tumor patients at the time of diagnosis, N = 79, tu03
represents the ADAM8 expression in the serum of tumor patients 3
months after treatment N = 35, and tu12 represents the ADAM8
expression in the serum of tumor patients 12 months after
treatment N = 10.
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Kaplan Meier curve (Figure 2) strong ADAM8 staining
in the tumor is associated with worse survival rates.
Unfortunately, in contrast to tumor expression, serum
levels of ADAM8 did not predict survival.
However, in this preliminary study the number of
patients was too small for a subgroup analysis of tumor
location and treatment type. To find a difference
between these subtypes a much larger group of patients
and probably a multi-center study would be necessary.
Conclusions
In summary tumor ADAM8 expression is a prognostic
marker for survival in contrast to serum levels. Patients
with high ADAM8 expression had a worse outcome
than patients with lower ADAM8 expression. These pre-
liminary results are promising but the clinical signifi-
cance of this finding has to be determined in larger
studies.
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